{
    "id": 3547,
    "fullName": "NRAS G12V",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "NRAS G12V is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). G12V confers a loss of function on Nras protein as indicated by accumulation of GTP-bound Nras, loss of GTPase-activating protein sensitivity, leading to increased downstream pathway activation in cell culture (PMID: 19966803).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2100,
                    "pubMedId": 19966803,
                    "title": "A restricted spectrum of NRAS mutations causes Noonan syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19966803"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4893,
        "geneSymbol": "NRAS",
        "terms": [
            "NRAS",
            "ALPS4",
            "CMNS",
            "N-ras",
            "NCMS",
            "NRAS1",
            "NS6"
        ]
    },
    "variant": "G12V",
    "createDate": "03/05/2015",
    "updateDate": "09/20/2018",
    "referenceTranscriptCoordinates": {
        "id": 162437,
        "transcript": "NM_002524",
        "gDna": "chr1:g.114716126C>A",
        "cDna": "c.35G>T",
        "protein": "p.G12V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring NRAS G12V demonstrated resistance to Erbitux (cetuximab) in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 3354,
                "profileName": "NRAS G12V"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10314,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring NRAS G12V in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 3354,
                "profileName": "NRAS G12V"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4490,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18238,
                "profileName": "EGFR exon 19 del NRAS G12V"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5785,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21619,
                "profileName": "BRAF V600E NRAS G12V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5786,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21619,
                "profileName": "BRAF V600E NRAS G12V"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3354,
            "profileName": "NRAS G12V",
            "profileTreatmentApproaches": [
                {
                    "id": 16445,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "NRAS G12V"
                },
                {
                    "id": 16446,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "NRAS G12V"
                },
                {
                    "id": 16450,
                    "name": "PIK3CA inhibitor",
                    "profileName": "NRAS G12V"
                },
                {
                    "id": 16449,
                    "name": "MEK1 Inhibitor",
                    "profileName": "NRAS G12V"
                },
                {
                    "id": 16448,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "NRAS G12V"
                },
                {
                    "id": 16447,
                    "name": "MEK2 Inhibitor",
                    "profileName": "NRAS G12V"
                }
            ]
        },
        {
            "id": 18238,
            "profileName": "EGFR exon 19 del NRAS G12V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21619,
            "profileName": "BRAF V600E NRAS G12V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 162437,
            "transcript": "NM_002524",
            "gDna": "chr1:g.114716126C>A",
            "cDna": "c.35G>T",
            "protein": "p.G12V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}